PORTLAND, OR, UNITED STATES, June 20, 2025 /EINPresswire.com/ -- The global nicotine replacement therapy (NRT) market is ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial. The setback blows a hole in the Big Pharma’s plans to challenge for ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury that resolved after the ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity.

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings, ...

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. (AP Photo/Mark Lennihan, File) A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

The Pfizer logo is displayed at the company's headquarters on Feb. 5, 2021, in New York. Pfizer reports earnings on Tuesday, July 30, 2024. Credit: AP/Mark Lennihan.

Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, the Big Pharma has vowed to advance a once-daily, modified-release ...

Sales for Pfizer’s COVID-19 vaccine and oral treatment declined nearly 70% annually during the first quarter, underscoring the company’s earnings headaches as heads turned toward weight loss ...